Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

mAbs

Fabrizio Maggi¹  Daniele Focosi²  Marco Tuccori³  Corrado Blandizzi³  Giulia Valdiserra⁴  Irma Convertino⁴  Sara Ferraro⁴  Emiliano Cappello⁴ 

[1] Division of Microbiology, Varese University Hospital, Varese, Italy;Pisa University Hospital, Pisa, Italy;Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Pisa, Italy;Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy;

关键词: COVID-19;    SARS-CoV-2;    monoclonal antibody;    VIR-7831;    LY-CoV555;    LY-CoV016;   

DOI  :  10.1080/19420862.2020.1854149

来源: DOAJ

【 摘 要 】

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials. We describe the structure, mechanism of action, and ongoing trials for VIR-7831, LY-CoV555, LY-CoV016, BGB-DXP593, REGN-COV2, and CT-P59. We speculate also on the next generation of these mAbs.

【 授权许可】

Unknown